Zynerba Pharmaceuticals (ZYNE) Given Buy Rating at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH restated their buy rating on shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) in a research note released on Monday, May 6th, AnalystRatings.com reports. They currently have a $26.00 price target on the stock.

“We continue to look for Zygel’s NDA filing in 1H’20 and approval in 2H’20 as we had anticipated this Fast Track designation.”,” the firm’s analyst commented.

Several other brokerages have also recently issued reports on ZYNE. ValuEngine raised shares of Zynerba Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, April 30th. Roth Capital assumed coverage on shares of Zynerba Pharmaceuticals in a research note on Tuesday, April 30th. They set a buy rating and a $36.00 target price on the stock. Canaccord Genuity started coverage on shares of Zynerba Pharmaceuticals in a research note on Monday, April 22nd. They set a

... read more at: https://techknowbits.com/2019/05/14/zynerba-pharmaceuticals-zyne-receives-buy-rating-from-ladenburg-thalm-sh-sh.html

Leave a Reply